Liang-Bo Wang,Alla Karpova,Marina A. Gritsenko,Jennifer E. Kyle,Song Cao,Yize Li,Dmitry Rykunov,Antonio Colaprico,Joseph H. Rothstein,Runyu Hong,Vasileios Stathias,MacIntosh Cornwell,Francesca Petralia,Yige Wu,Boris Reva,Karsten Krug,Pietro Pugliese,Emily Kawaler,Lindsey K. Olsen,Wen-Wei Liang,Xiaoyu Song,Yongchao Dou,Michael C. Wendl,Wagma Caravan,Wenke Liu,Daniel Cui Zhou,Jiayi Ji,Chia-Feng Tsai,Vladislav A. Petyuk,Jamie Moon,Weiping Ma,Rosalie K. Chu,Karl K. Weitz,Ronald J. Moore,Matthew E. Monroe,Rui Zhao,Xiaolu Yang,Seungyeul Yoo,Azra Krek,Alexis Demopoulos,Houxiang Zhu,Matthew A. Wyczalkowski,Joshua F. McMichael,Brittany L. Henderson,Caleb M. Lindgren,Hannah Boekweg,Shuangjia Lu,Jessika Baral,Lijun Yao,Kelly G. Stratton,Lisa M. Bramer,Erika Zink,Sneha P. Couvillion,Kent J. Bloodsworth,Shankha Satpathy,Weiva Sieh,Simina M. Boca,Stephan Schürer,Feng Chen,Maciej Wiznerowicz,Karen A. Ketchum,Emily S. Boja,Christopher R. Kinsinger,Ana I. Robles,Tara Hiltke,Mathangi Thiagarajan,Alexey I. Nesvizhskii,Bing Zhang,D.R. Mani,Michele Ceccarelli,Xi S. Chen,Sandra L. Cottingham,Qing Kay Li,Albert H. Kim,David Fenyö,Kelly V. Ruggles,Henry Rodriguez,Mehdi Mesri,Samuel H. Payne,Adam C. Resnick,Pei Wang,Richard D. Smith,Antonio Iavarone,Milan G. Chheda,Jill S. Barnholtz-Sloan,Karin D. Rodland,Tao Liu,Li Ding,Clinical Proteomic Tumor Analysis Consortium,Anupriya Agarwal,Mitual Amin,Eunkyung An,Matthew L. Anderson,David W. Andrews,Thomas Bauer,Chet Birger,Michael J. Birrer,Lili Blumenberg,William E. Bocik,Uma Borate,Melissa Borucki,Meghan C. Burke,Shuang Cai,Anna P. Calinawan,Steven A. Carr,Sandra Cerda,Daniel W. Chan,Alyssa Charamut,Lin S. Chen,David Chesla,Arul M. Chinnaiyan,Shrabanti Chowdhury,Marcin P. Cieślik,David J. Clark,Houston Culpepper,Tomasz Czernicki,Fulvio D'Angelo,Jacob Day,Stephanie De Young,Emek Demir,Saravana Mohan Dhanasekaran,Rajiv Dhir,Marcin J. Domagalski,Brian Druker,Elizabeth Duffy,Maureen Dyer,Nathan J. Edwards,Robert Edwards,Kimberly Elburn,Matthew J. Ellis,Jennifer Eschbacher,Alicia Francis,Stacey Gabriel,Nikolay Gabrovski,Luciano Garofano,Gad Getz,Michael A. Gillette,Andrew K. Godwin,Denis Golbin,Ziad Hanhan,Linda I. Hannick,Pushpa Hariharan,Barbara Hindenach,Katherine A. Hoadley,Galen Hostetter,Chen Huang,Eric Jaehnig,Scott D. Jewell,Nan Ji,Corbin D. Jones,Alcida Karz,Wojciech Kaspera,Lyndon Kim,Ramani B. Kothadia,Chandan Kumar-Sinha,Jonathan Lei,Felipe D. Leprevost,Kai Li,Yuxing Liao,Jena Lilly,Hongwei Liu,Jan Lubínski,Rashna Madan,William Maggio,Ewa Malc,Anna Malovannaya,Sailaja Mareedu,Sanford P. Markey,Annette Marrero-Oliveras,Nina Martinez,Nicollette Maunganidze,Jason E. McDermott,Peter B. McGarvey,John McGee,Piotr Mieczkowski,Simona Migliozzi,Francesmary Modugno,Rebecca Montgomery,Chelsea J. Newton,Gilbert S. Omenn,Umut Ozbek,Oxana V. Paklina,Amanda G. Paulovich,Amy M. Perou,Alexander R. Pico,Paul D. Piehowski,Dimitris G. Placantonakis,Larisa Polonskaya,Olga Potapova,Barbara Pruetz,Liqun Qi,Shakti Ramkissoon,Adam Resnick,Shannon Richey,Gregory Riggins,Karna Robinson,Nancy Roche,Daniel C. Rohrer,Brian R. Rood,Larissa Rossell,Sara R. Savage,Eric E. Schadt,Yan Shi,Zhiao Shi,Yvonne Shutack,Shilpi Singh,Tara Skelly,Lori J. Sokoll,Jakub Stawicki,Stephen E. Stein,James Suh,Wojciech Szopa,Dave Tabor,Donghui Tan,Darlene Tansil,Ratna R. Thangudu,Cristina Tognon,Elie Traer,Shirley Tsang,Jeffrey Tyner,Ki Sung Um,Dana R. Valley,Suhas Vasaikar,Negin Vatanian,Uma Velvulou,Michael Vernon,Weiqing Wan,Junmei Wang,Alex Webster,Bo Wen,Jeffrey R. Whiteaker,George D. Wilson,Yuriy Zakhartsev,Robert Zelt,Hui Zhang,Liwei Zhang,Zhen Zhang,Grace Zhao,Jun Zhu

Abstract:Glioblastoma (GBM) is the most aggressive nervous system cancer. Understanding its molecular pathogenesis is crucial to improving diagnosis and treatment. Integrated analysis of genomic, proteomic, post-translational modification and metabolomic data on 99 treatment-naive GBMs provides insights to GBM biology. We identify key phosphorylation events (e.g., phosphorylated PTPN11 and PLCG1) as potential switches mediating oncogenic pathway activation, as well as potential targets for EGFR-, TP53-, and RB1-altered tumors. Immune subtypes with distinct immune cell types are discovered using bulk omics methodologies, validated by snRNA-seq, and correlated with specific expression and histone acetylation patterns. Histone H2B acetylation in classical-like and immune-low GBM is driven largely by BRDs, CREBBP, and EP300. Integrated metabolomic and proteomic data identify specific lipid distributions across subtypes and distinct global metabolic changes in IDH-mutated tumors. This work highlights biological relationships that could contribute to stratification of GBM patients for more effective treatment.

Supplementary Data from Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas

Hsp90 Inhibitor-Loaded IR780 Micelles for Mitochondria-Targeted Mild-Temperature Photothermal Therapy in Xenograft Models of Human Breast Cancer

Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

Novel HSP90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig2-positive Glioma Tumor-Initiating Cells.

Supplementary Data from Mitochondrial Calcium Uniporter Drives Metastasis and Confers a Targetable Cystine Dependency in Pancreatic Cancer

Supplementary Data from Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response

Supplementary Data 1 from Dual Role of CXCL8 in Maintaining the Mesenchymal State of Glioblastoma Stem Cells and M2-Like Tumor-Associated Macrophages

Supplementary Data 1 from A Phase 1/2 Multicenter Randomized Trial of Local Ablation Plus Toripalimab Versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma

The development of cancers research based on mitochondrial heat shock protein 90

Supplementary Data from Regorafenib Promotes Antitumor Immunity Via Inhibiting PD-L1 and IDO1 Expression in Melanoma

Supplementary Data from GOT2 Silencing Promotes Reprogramming of Glutamine Metabolism and Sensitizes Hepatocellular Carcinoma to Glutaminase Inhibitors

Supplementary Tables 1-3, Figures 1-3 from Molecular Target Characterization and Antimyeloma Activity of the Novel, Insulin-like Growth Factor 1 Receptor Inhibitor, GTx-134

Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma

Supplementary Data from Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis

Exploratory Phase I Study of HF1K16 for the Treatment of Patients with Refractory/recurrent Advanced Glioma: Preliminary Efficacy and Mechanism As a Monotherapy

Proteogenomic and metabolomic characterization of human glioblastoma

Supplementary Table S4 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

Supplementary Data from Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial

A multicenter open-label phase 1 study evaluating the safety and tolerability of HMPL-306 in patients with locally advanced or metastatic solid tumors with IDH mutations.

Supplementary Data from Galectin-3 Targeted Therapy with a Small Molecule Inhibitor Activates Apoptosis and Enhances Both Chemosensitivity and Radiosensitivity in Papillary Thyroid Cancer

Abstract 1672: Preclinical Evaluation of WXFL1024H251, a Potent Second-Generation HSP90 Inhibitor